
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
List of bestselling drugs
Introduction
The following is a list of the top 200 pharmaceutical products ranked by sales.
| Rank 2006 | Brand Name(s) | Generic Name | Sales 2006 (USDÂ millions) | Change from 2005 | Company(ies) | Disease/Medical Use | First Approval Date |
|---|---|---|---|---|---|---|---|
| 1 | Lipitor | Atorvastatin | 14,385 | 7% | Pfizer, Astellas Pharma | Cholesterol | Dec-1996 |
| 2 | Advair, Seretide | Fluticasone + Salmeterol | 6,129 | 12% | GlaxoSmithKline | Asthma | Aug-2000 |
| 3 | Plavix, Iscover | Clopidogrel | 6,057 | -5% | Bristol-Myers Squibb, Sanofi-Aventis | Thrombotic events | Nov-1997 |
| 4 | Nexium | Esomeprazole | 5,182 | 12% | AstraZeneca | Gastrointestinal disorders | Mar-2000 |
| 5 | Norvasc | Amlodipine | 4,866 | 3% | Pfizer | Hypertension | Jul-1992 |
| 6 | Remicade | Infliximab | 4,428 | 23% | Johnson & Johnson, Schering-Plough, Tanabe | Rheumatoid arthritis | Aug-1998 |
| 7 | Enbrel | Etanercept | 4,379 | 20% | Amgen, Wyeth | Rheumatoid arthritis | Nov-1998 |
| 8 | Zyprexa | Olanzapine | 4,364 | 4% | Eli Lilly | Schizophrenia | Sep-1996 |
| 9 | Diovan | Valsartan | 4,223 | 15% | Novartis | Hypertension | Dec-1996 |
| 10 | Risperdal | Risperidone | 4,183 | 18% | Johnson & Johnson | Schizophrenia | Dec-1993 |
| 11 | Aranesp | Darbepoetin alfa | 4,121 | 26% | Amgen | Anemia | Jun-2001 |
| 12 | Rituxan, MabThera | Rituximab | 3,861 | 16% | Roche, Genentech, Biogen Idec, Chugai Pharmaceutical | Non-Hodgkin’s lymphoma | Nov-1997 |
| 13 | Effexor | Venlafaxine | 3,722 | 8% | Wyeth | Depression | Dec-1993 |
| 14 | Protonix, Pantozol, Pantoloc | Pantoprazole | 3,621 | 4% | Wyeth, Altana, Solvay | Gastrointestinal disorders | Feb-2000 |
| 15 | Singulair | Montelukast | 3,579 | 20% | Merck & Co. | Asthma | Feb-1998 |
| 16 | Seroquel | Quetiapine | 3,560 | 23% | AstraZeneca, Astellas Pharma | Schizophrenia | Sep-1997 |
| 17 | Prevacid, Takepron | Lansoprazole | 3,425 | 3% | TAP Pharmaceuticals, Takeda Pharmaceutical | Gastrointestinal disorders | May-1995 |
| 18 | Procrit, Eprex | Erythropoietin | 3,180 | -4% | Johnson & Johnson | Anemia | Dec-1990 |
| 19 | Cozaar, Hyzaar | Losartan | 3,163 | 4% | Merck & Co. | Hypertension | Apr-1995 |
| 20 | Fosamax | Alendronate | 3,134 | -2% | Merck & Co. | Osteoporosis | Sep-1995 |
| 21 | Herceptin | Trastuzumab | 3,134 | 83% | Roche, Genentech, Chugai Pharmaceutical | Breast cancer | Sep-1998 |
| 22 | Lovenox, Clexane | Enoxaparin | 3,059 | 14% | Sanofi-Aventis | Deep-vein thrombosis | Mar-1993 |
| 23 | Avandia, Avandamet, Avandaryl | Rosiglitazone | 3,043 | 26% | GlaxoSmithKline | Type 2 diabetes | May-1999 |
| 24 | Actos | Pioglitazone | 2,880 | 25% | Takeda Pharmaceutical, Eli Lilly | Type 2 diabetes | Jul-1999 |
| 25 | Zocor | Simvastatin | 2,803 | -36% | Merck & Co. | Cholesterol | Dec-1991 |
| 26 | Copaxone | Glatiramer | 2,757 | 19% | Teva Pharmaceutical Industries, Sanofi-Aventis | Multiple sclerosis | Dec-1996 |
| 27 | AcipHex, Pariet | Rabeprazole | 2,729 | -4% | Eisai, Johnson & Johnson | Gastrointestinal disorders | Aug-1999 |
| 28 | Neulasta | Filgrastim | 2,710 | 18% | Amgen | Neutropenia | Jan-2002 |
| 29 | Lexapro, Cipralex | Escitalopram | 2,696 | 16% | Forest Laboratories, H. Lundbeck | Major depressive disorder | Aug-2002 |
| 30 | Gleevec, Glivec | Imatinib | 2,554 | 18% | Novartis | Leukemia | May-2001 |
| 31 | Ambien, Stilnox | Zolpidem | 2,545 | 33% | Sanofi-Aventis | Insomnia | Dec-1992 |
| 32 | Aricept | Donepezil | 2,519 | 24% | Eisai, Pfizer | Alzheimer’s disease | Nov-1996 |
| 33 | Epogen | Erythropoietin | 2,511 | 2% | Amgen | Anemia | Jun-1989 |
| 34 | Zyrtec, Cirrus | Cetirizine | 2,377 | 9% | Pfizer, UCB, Daiichi Sankyo | Allergic rhinitis | Dec-1995 |
| 35 | Avapro, Aprovel, Avalide | Irbesartan | 2,372 | 13% | Sanofi-Aventis, Bristol-Myers Squibb | Hypertension | Sep-1997 |
| 36 | Avastin | Bevacizumab | 2,364 | 78% | Roche, Genentech | Colorectal cancer | Feb-2004 |
| 37 | Taxotere | Docetaxel | 2,201 | 9% | Sanofi-Aventis | Cancer | Oct-1995 |
| 38 | Eloxatin, Eloxatine | Oxaliplatin | 2,127 | 8% | Sanofi-Aventis | Colorectal cancer | Aug-2002 |
| 39 | Zoloft | Sertraline | 2,110 | -35% | Pfizer | Depression | Dec-1991 |
| 40 | Tamiflu | Oseltamivir | 2,096 | 69% | Roche, Chugai Pharmaceutical | Influenza | Oct-1999 |
| 41 | Lantus | Insulin analog | 2,093 | 37% | Sanofi-Aventis | Type 2 diabetes and type 1 diabetes | Apr-2000 |
| 42 | Crestor | Rosuvastatin | 2,049 | 61% | AstraZeneca, Shionogi | Cholesterol | Nov-2002 |
| 43 | Humira | Adalimumab | 2,044 | 46% | Abbott Laboratories | Rheumatoid arthritis | Dec-2002 |
| 44 | Celebrex | Celecoxib | 2,039 | 18% | Pfizer | Osteoarthritis and rheumatoid arthritis | Dec-1998 |
| 45 | Topamax | Topiramate | 2,027 | 21% | Johnson & Johnson | Seizures | Dec-1996 |
| 46 | Prevnar | vaccine | 1,961 | 30% | Wyeth | Pneumococcal disease | Feb-2000 |
| 47 | Vytorin | Ezetimibe + Simvastatin | 1,955 | 90% | Merck & Co., Schering-Plough | Cholesterol | Jul-2004 |
| 48 | Zetia | Ezetimibe | 1,929 | 38% | Merck & Co., Schering-Plough | Cholesterol | Oct-2002 |
| 49 | Wellbutrin | Bupropion | 1,926 | 26% | GlaxoSmithKline, Biovail | Depression | Aug-2003 |
| 50 | Abilify | Aripiprazole | 1,900 | 1% | Otsuka Pharmaceutical, Bristol-Myers Squibb | Schizophrenia | Nov-2002 |
| 51 | Lamictal | Lamotrigine | 1,843 | 19% | GlaxoSmithKline | Seizures | Dec-1994 |
| 52 | Toprol, Seloken | Metoprolol | 1,795 | 3% | AstraZeneca | Hypertension | Jan-1992 |
| 53 | NeoRecormon, Epogin | Erythropoietin | 1,777 | -1% | Roche, Chugai Pharmaceutical | Anemia | Jul-1997 |
| 54 | Atacand, Blopress | Candesartan | 1,768 | 8% | Takeda Pharmaceutical, AstraZeneca | Hypertension | Oct-1997 |
| 55 | Spiriva | Tiotropium | 1,735 | 45% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Apr-2002 |
| 56 | Avonex | Interferon beta-1a | 1,707 | 11% | Biogen Idec | Multiple sclerosis | May-1996 |
| 57 | Viagra | Sildenafil | 1,657 | 1% | Pfizer | Erectile dysfunction | Mar-1998 |
| 58 | Micardis | Telmisartan | 1,645 | 35% | Boehringer Ingelheim, Astellas Pharma | Hypertension | Nov-1998 |
| 59 | Actonel | Risedronate | 1,619 | -4% | Procter & Gamble, Sanofi-Aventis | Osteoporosis | Mar-1998 |
| 60 | Lupron, Leuplin | Leuprolide | 1,579 | 1% | Takeda Pharmaceutical, TAP Pharmaceuticals | Prostate cancer | Jan-1989 |
| 61 | TriCor, Lipanthyl | Fenofibrate | 1,567 | 38% | Abbott Laboratories, Solvay | Cholesterol | Feb-1998 |
| 62 | Zofran | Ondansetron | 1,567 | 3% | GlaxoSmithKline | Nausea and vomiting | Dec-1992 |
| 63 | Valtrex | Valaciclovir | 1,563 | 24% | GlaxoSmithKline | Herpes | Jun-1995 |
| 64 | Levaquin, Floxin | Levofloxacin | 1,530 | 3% | Johnson & Johnson | Bacterial infections | Dec-1996 |
| 65 | Arimidex | Anastrozole | 1,508 | 28% | AstraZeneca | Breast cancer | Dec-1995 |
| 66 | Prograf | Tacrolimus | 1,499 | 20% | Astellas Pharma | Transplant rejection | Apr-1993 |
| 67 | CellCept | Mycophenolate mofetil | 1,470 | 8% | Roche, Chugai Pharmaceutical | Transplant rejection | May-1995 |
| 68 | Xalatan, Xalacom | Latanoprost | 1,453 | 6% | Pfizer | Intraocular pressure | Jun-1996 |
| 69 | Rebif | Interferon beta-1a | 1,452 | 14% | Serono | Multiple sclerosis | Feb-1998 |
| 70 | Coreg | Carvedilol | 1,441 | 38% | GlaxoSmithKline | Hypertension | Sep-1995 |
| 71 | Gemzar | Gemcitabine | 1,408 | 5% | Eli Lilly | Cancer | May-1996 |
| 72 | Prilosec, Losec | Omeprazole | 1,371 | -17% | AstraZeneca | Gastrointestinal disorders | Sep-1989 |
| 73 | Benicar, Olmetec | Olmesartan | 1,370 | 73% | Daiichi Sankyo, Forest Laboratories | Hypertension | Apr-2002 |
| 74 | Lotrel | Amlodipine + Benazepril | 1,352 | 26% | Novartis | Hypertension | Jun-1999 |
| 75 | Cymbalta | Duloxetine | 1,316 | 94% | Eli Lilly | Depressive disorder | Aug-2004 |
| 76 | Imitrex, Imigran | Sumatriptan | 1,315 | 4% | GlaxoSmithKline | Migraine | Dec-1992 |
| 77 | Depakote | Valproate | 1,308 | 19% | Abbott Laboratories | Seizures | Mar-1983 |
| 78 | Humalog | Insulin analog | 1,300 | 8% | Eli Lilly | Diabetes | Apr-1996 |
| 79 | Duragesic | Fentanyl | 1,295 | -18% | Johnson & Johnson | Pain | Aug-1990 |
| 80 | Pulmicort | Budesonide | 1,292 | 11% | AstraZeneca | Asthma | Jun-1997 |
| 81 | Zometa | Zoledronate | 1,283 | 5% | Novartis | Hypercalcemia | Aug-2000 |
| 82 | Betaseron, Betaferon | Interferon beta-1b | 1,245 | 14% | Schering AG | Multiple sclerosis | Jul-1993 |
| 83 | Delix, Tritace | Ramipril | 1,227 | -3% | Sanofi-Aventis | Hypertension | Jul-2000 |
| 84 | Flovent, Flixotide | Fluticasone | 1,219 | 5% | GlaxoSmithKline | Asthma | Mar-1996 |
| 85 | Neupogen | Filgrastim | 1,213 | 0% | Amgen | Neutropenia | Feb-1991 |
| 86 | Casodex | Bicalutamide | 1,206 | 7% | AstraZeneca | Prostate cancer | Oct-1995 |
| 87 | Pravachol | Pravastatin | 1,197 | -47% | Bristol-Myers Squibb | Cholesterol | Oct-1991 |
| 88 | Truvada | Tenofovir + Emtricitabine | 1,194 | 110% | Gilead Sciences | HIV infection | Aug-2004 |
| 89 | Symbicort | Budesonide + Formoterol | 1,184 | 18% | AstraZeneca | Asthma | Aug-2000 |
| 90 | Pegasys | Pegylated interferon alfa-2a | 1,171 | 5% | Roche, Chugai Pharmaceutical | Hepatitis C | Jun-2002 |
| 91 | Evista | Raloxifene | 1,159 | 4% | Eli Lilly, Chugai Pharmaceutical | Osteoporosis | Dec-1997 |
| 92 | Flomax | Tamsulosin | 1,158 | 28% | Boehringer Ingelheim | Benign prostatic hypertrophy | Oct-1997 |
| 93 | Lyrica | Pregabalin | 1,156 | 297% | Pfizer | Neuropathic pain | Jul-2004 |
| 94 | Paxil, Seroxat | Paroxetine | 1,147 | 3% | GlaxoSmithKline | Depression | Dec-1992 |
| 95 | Kaletra | Lopinavir | 1,135 | 13% | Abbott Laboratories | HIV infection | Mar-2001 |
| 96 | Detrol | Tolterodine | 1,100 | 11% | Pfizer | Overactive bladder | Mar-1998 |
| 97 | Harnal | Tamsulosin | 1,085 | -8% | Astellas Pharma | Benign prostatic hypertrophy | Jul-1992 |
| 98 | Erbitux | Cetuximab | 1,075 | 56% | Bristol-Myers Squibb, Merck KGaA | Colorectal cancer | Feb-2004 |
| 99 | Synagis | Palivizumab | 1,065 | -9% | MedImmune | Respiratory syncytial virus | Jun-1998 |
| 100 | Augmentin | Co-amoxiclav | 1,055 | -13% | GlaxoSmithKline | Bacterial infections | Aug-1984 |
| 101 | Premarin, Prempro, Premphase | Estrogen | 1,051 | 16% | Wyeth | Menopausal symptoms | Nov-1995 |
| 102 | Ortho contraceptives | Estrogen + Progesterone | 1,016 | -11% | Johnson & Johnson | Contraception | Apr-1984 |
| 103 | Zoladex | Goserelin | 1,008 | 0% | AstraZeneca | Prostate cancer | Dec-1989 |
| 104 | Cerezyme | Imiglucerase | 1,007 | 8% | Genzyme | Gaucher disease | Apr-1991 |
| 105 | Cravit | Levofloxacin | 1,002 | 2% | Daiichi Sankyo, Santen Pharmaceutical | Bacterial infections | Jun-1909 |
| 106 | Yasmin | Drospirenone | 998 | 36% | Schering AG | Prevention of pregnancy | Aug-2000 |
| 107 | Kogenate | Recombinant factor VIII | 989 | 19% | Bayer | Hemophilia | Feb-1993 |
| 108 | Botox | Botulin toxin | 982 | 18% | Allergan | Cervical dystonia | Dec-1989 |
| 109 | Lamisil | Terbinafine | 978 | -14% | Novartis | Fungal infections | Dec-1992 |
| 110 | Combivir | Lamivudine + Zidovudine | 977 | -8% | GlaxoSmithKline | HIV infection | Sep-1997 |
| 111 | Zosyn, Tazocin | Piperacillin | 972 | 9% | Wyeth | Bacterial infections | Oct-1993 |
| 112 | Cialis | Tadalafil | 971 | 30% | Lilly, Lilly Icos | Erectile dysfunction | Nov-2002 |
| 113 | Keppra | Levetiracetam | 956 | 36% | UCB | Seizures | Nov-1999 |
| 114 | NovoSeven | Factor VII | 948 | 11% | Novo Nordisk | Bleeding due to hemophilia | Feb-1996 |
| 115 | Infanrix, Pediarix | vaccine | 945 | 21% | GlaxoSmithKline | Diphtheria, tetanus, and pertussis | Jan-1996 |
| 116 | Nasonex | Mometasone | 944 | 28% | Schering-Plough | Allergic rhinitis | Oct-1997 |
| 117 | Reyataz | Atazanavir | 931 | 34% | Bristol-Myers Squibb | HIV infection | Jan-2003 |
| 118 | Concerta | Methylphenidate | 930 | 20% | Johnson & Johnson | Attention-deficit hyperactivity disorder | Aug-2000 |
| 119 | Humulin | Recombinant human insulin | 925 | -8% | Eli Lilly | Diabetes | Oct-1982 |
| 120 | Neoral, Sandimmun | Ciclosporin | 918 | -4% | Novartis | Transplant rejection | Jul-1995 |
| 121 | Sandostatin | Somatostatin | 915 | 2% | Novartis | Acromegaly | Oct-1988 |
| 122 | Camptosar | Irinotecan | 903 | -1% | Pfizer | Colorectal cancer | Jun-1996 |
| 123 | Engerix-B, Havrix, Twinrix | vaccine | 886 | 10% | GlaxoSmithKline | Hepatitis | Aug-1989 |
| 124 | Allegra, Telfast | Fexofenadine | 864 | -49% | Sanofi-Aventis | Allergic rhinitis | Jul-1996 |
| 125 | Adderall | Amphetamine | 864 | 18% | Shire Pharmaceuticals | Attention-deficit hyperactivity disorder | Oct-2001 |
| 126 | Combivent | Ipratropium + Salbutamol | 843 | 20% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Oct-1996 |
| 127 | Peg-Intron | Pegylated interferon alfa-2b | 837 | 11% | Schering-Plough | Hepatitis C | May-2000 |
| 128 | Adalat | Nifedipine | 825 | 0% | Bayer | Hypertension | Nov-1985 |
| 129 | Avelox, Avalox | Moxifloxacin | 822 | 17% | Bayer, Schering-Plough, Shionogi | Bacterial infections | Dec-1999 |
| 130 | Mobic | Meloxicam | 818 | -66% | Boehringer Ingelheim, Daiichi Sankyo | Osteoarthritis and rheumatoid arthritis | Feb-1996 |
| 131 | Biaxin | Clarithromycin | 816 | -23% | Abbott Laboratories | Bacterial infections | Oct-1991 |
| 132 | Mevalotin | Pravastatin | 799 | -35% | Daiichi Sankyo | Cholesterol | Jun-1909 |
| 133 | Ultane, Sevorane | Sevoflurane | 799 | -9% | Abbott Laboratories | Anesthesia | Jun-1995 |
| 134 | Genotropin | Somatropin | 795 | -2% | Pfizer | Growth failure | Aug-1995 |
| 135 | Sustiva | Efavirenz | 791 | 16% | Bristol-Myers Squibb | HIV infection | Sep-1998 |
| 136 | Zyvox | Linezolid | 782 | 27% | Pfizer | Bacterial infections | Apr-2000 |
| 137 | Xeloda | Capecitabine | 775 | 22% | Roche, Chugai Pharmaceutical | Cancer | Jun-1909 |
| 138 | Geodon, Zeldox | Ziprasidone | 758 | 29% | Pfizer | Schizophrenia | Feb-2001 |
| 139 | Cipro, Ciprobay | Ciprofloxacin | 755 | -6% | Bayer, Schering-Plough | Bacterial infections | Oct-1987 |
| 140 | Provigil | Modafinil | 735 | 43% | Cephalon | Sleepiness | Dec-1998 |
| 141 | Lescol | Fluvastatin | 725 | -5% | Novartis | Cholesterol | Dec-1993 |
| 142 | Clarinex, Aerius | Desloratadine | 722 | 12% | Schering-Plough | Allergic rhinitis | Dec-2001 |
| 143 | Femara | Letrozole | 722 | 35% | Novartis, Chugai Pharmaceutical | Breast cancer | Jul-1997 |
| 144 | Trileptal | Oxcarbazepine | 721 | 17% | Novartis | Seizures | Nov-1999 |
| 145 | Tracleer | Bosentan | 717 | 42% | Actelion | Pulmonary arterial hypertension | Nov-2001 |
| 146 | Primaxin | Imipenem + Cilastatin | 705 | -5% | Merck & Co. | Bacterial infections | Nov-1985 |
| 147 | Temodar | Temozolomide | 703 | 20% | Schering-Plough | Anaplastic astrocytoma | Aug-1999 |
| 148 | Trusopt, Cosopt | Dorzolamide | 697 | 13% | Merck & Co. | Intraocular pressure | Dec-1994 |
| 149 | Voltaren | Diclofenac | 690 | 0% | Novartis | Osteoarthritis and rheumatoid arthritis | Jul-1998 |
| 150 | Viread | Tenofovir | 689 | -12% | Gilead Sciences | HIV infection | Oct-2001 |
| 151 | Sifrol | Pramipexole | 673 | 23% | Boehringer Ingelheim | Parkinson’s disease | Oct-1997 |
| 152 | Namenda | Memantine | 660 | 30% | Forest Laboratories | Alzheimer disease | Oct-2003 |
| 153 | Altace | Ramipril | 653 | 18% | King Pharmaceuticals | Cardiovascular events | Jan-1991 |
| 154 | Byetta | Exenatide | 649 | 464% | Amylin Pharmaceuticals, Eli Lilly | Type 2 diabetes | Apr-2005 |
| 155 | Tarceva | Erlotinib | 649 | 110% | Roche, Genentech | Non-small cell lung cancer | Nov-2004 |
| 156 | Zithromax, Zmax | Azithromycin | 638 | -68% | Pfizer | Bacterial infections | Nov-1991 |
| 157 | Omnicef | Cefdinir | 637 | 29% | Abbott Laboratories | Bacterial infections | Dec-1997 |
| 158 | Proscar | Finasteride | 619 | -16% | Merck & Co. | Benign prostatic hypertrophy | Jun-1992 |
| 159 | Alimta | Pemetrexed | 612 | 32% | Eli Lilly | Non-small cell lung cancer | Feb-2004 |
| 160 | Merrem | Meropenem | 604 | 20% | AstraZeneca | Bacterial infections | Jun-1996 |
| 161 | Forteo | Teriparatide | 594 | 53% | Eli Lilly | Osteoporosis | Nov-2002 |
| 162 | Strattera | Atomoxetine | 579 | 5% | Eli Lilly | Attention-deficit hyperactivity disorder | Nov-2002 |
| 163 | Actiq | Fentanyl | 578 | 40% | Cephalon | Cancer pain | Nov-1998 |
| 164 | Flonase, Flixonase | Fluticasone | 575 | -52% | GlaxoSmithKline | Allergic rhinitis | Oct-1994 |
| 165 | Amaryl | Glimepiride | 567 | -33% | Sanofi-Aventis | Type 2 diabetes | Nov-1995 |
| 166 | Lidoderm | Lidocaine | 567 | 35% | Endo Pharmaceuticals | Pain | Mar-1999 |
| 167 | Lunesta | Eszopiclone | 567 | 72% | Sepracor | Insomnia | Dec-2004 |
| 168 | Boniva, Bonviva | Ibandronate | 565 | 454% | Roche, GlaxoSmithKline | Osteoporosis | Mar-2005 |
| 169 | Taxol | Paclitaxel | 563 | -25% | Bristol-Myers Squibb | Cancer | Dec-1992 |
| 170 | Zelnorm, Zelmac | Tegaserod | 561 | 34% | Novartis | Irritable bowel syndrome | Mar-2002 |
| 171 | Renagel | Sevelamer | 559 | 23% | Genzyme, Roche, Chugai Pharmaceutical | Hyperphosphatemia | Oct-1998 |
| 172 | Norditropin | Human growth hormone | 557 | 19% | Novo Nordisk | Growth hormone deficiency | Jun-1909 |
| 173 | Xopenex | Levalbuterol | 555 | 29% | Sepracor | Bronchospasm | Mar-1999 |
| 174 | Xenical | Orlistat | 553 | 9% | Roche | Obesity | Jul-1998 |
| 175 | Vasotec, Vaseretic | Enalapril | 547 | -12% | Merck & Co. | Hypertension | Dec-1985 |
| 176 | Serevent | Salmeterol | 538 | -10% | GlaxoSmithKline | Asthma | Feb-1994 |
| 177 | Cardura | Doxazosin | 538 | -8% | Pfizer | Hypertension | Nov-1990 |
| 178 | Synthroid | Levothyroxine | 534 | -4% | Abbott Laboratories | Hypothyroidism | May-1909 |
| 179 | Gonal-f | Follitropin alfa | 533 | -3% | Serono | Infertility | Oct-1995 |
| 180 | Gaster | Famotidine | 532 | -10% | Astellas Pharma | Gastrointestinal disorders | Jun-1909 |
| 181 | Cancidas | Caspofungin | 530 | -7% | Merck & Co. | Fungal infections | Jan-2001 |
| 182 | Exelon | Rivastigmine | 525 | 12% | Novartis | Alzheimer’s disease | May-1998 |
| 183 | Vfend | Voriconazole | 515 | 30% | Pfizer | Fungal infections | Mar-2002 |
| 184 | Amlodin | Amlodipine | 506 | 4% | Dainippon Sumitomo | Hypertension, angina pectoris | n/a |
| 185 | Niaspan | Niacin | 498 | 13% | Kos Pharmaceuticals | Cholesterol | Jul-1997 |
| 186 | Neurontin | Gabapentin | 496 | -22% | Pfizer | Seizures | Dec-1993 |
| 187 | Trizivir | Abacavir + Lamivudine + Zidovudine | 496 | -10% | GlaxoSmithKline | HIV infection | Nov-2000 |
| 188 | Requip | Ropinirole | 496 | 74% | GlaxoSmithKline | Parkinson disease | Sep-1997 |
| 189 | Follistim, Puregon | Follitropin beta | 482 | 8% | Akzo Nobel | Infertility | Sep-1997 |
| 190 | Basen | Voglibose | 476 | -13% | Takeda Pharmaceutical | Hyperglycemia | Jun-1909 |
| 191 | Levitra | Vardenafil | 474 | 19% | Bayer, GlaxoSmithKline | Erectile dysfunction | Mar-2003 |
| 192 | Glucophage | Metformin | 459 | -16% | Merck KGaA, Bristol-Myers Squibb | Type 2 diabetes | Dec-1994 |
| 193 | Concor | Bisoprolol | 455 | 4% | Merck KGaA | Hypertension | Jul-1992 |
| 194 | Epzicom, Kixeva | Abacavir + Lamivudine | 446 | 107% | GlaxoSmithKline | HIV infection | Aug-2004 |
| 195 | Xatral | Alfuzosin | 443 | 8% | Sanofi-Aventis | Benign prostatic hypertrophy | Jan-2000 |
| 196 | Diflucan | Fluconazole | 435 | -13% | Pfizer | Fungal infections | Jan-1990 |
| 197 | Thalomid | Thalidomide | 433 | 12% | Celgene | Erythema nodosum leprosum | Jul-1998 |
| 198 | Zantac | Ranitidine | 429 | -18% | GlaxoSmithKline | Gastrointestinal disorders | Jun-1983 |
| 199 | Xolair | Omalizumab | 429 | 32% | Roche, Genentech | Asthma | Jun-2003 |
| 200 | Claritin | Loratadine | 418 | -5% | Schering-Plough, Shionogi | Allergic rhinitis | Apr-1993 |
Source: MedAdNews 200 – World’s Best-Selling Medicines, MedAdNews, July 2007
